Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of

Deborah Mueller1, Christian Puelacher1,2, Ursina Honegger1

  • 1Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.

Clinical Chemistry
|August 12, 2018
PubMed

Insights

High-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) show similar moderate accuracy for detecting functionally relevant coronary artery disease (fCAD). Both troponins also demonstrated comparable prognostic value for major adverse cardiac events.

Area of Science:

  • Cardiology
  • Biomarkers
  • Diagnostic Imaging

Background:

  • Coronary artery disease (CAD) diagnosis relies on various methods.
  • High-sensitivity cardiac troponin assays (hs-cTnI and hs-cTnT) are crucial biomarkers.
  • Direct comparison of hs-cTnI and hs-cTnT in detecting functionally relevant CAD (fCAD) is needed.

Purpose of the Study:

  • To directly compare the diagnostic accuracy of hs-cTnI and hs-cTnT.
  • To evaluate the prognostic performance of hs-cTnI and hs-cTnT for major adverse cardiac events (MACE).
  • To assess the utility of sex-specific cutoffs for troponin assays.

Main Methods:

  • Prospective study including patients with suspected fCAD.
  • fCAD diagnosis confirmed by myocardial perfusion imaging and coronary angiography.
  • hs-cTnI and hs-cTnT levels measured; diagnostic accuracy assessed via ROC curves.
  • Prognostic performance evaluated for 2-year MACE using multivariable models.

Main Results:

  • Overall fCAD prevalence was 29.7%.
  • hs-cTnI and hs-cTnT demonstrated comparable diagnostic accuracy for fCAD in all patients, women, and men.
  • Sex-specific cutoffs may optimize sensitivity and specificity.
  • Both troponins were strong independent predictors of MACE with similar prognostic accuracy.

Conclusions:

  • hs-cTnI and hs-cTnT offer moderate and comparable diagnostic accuracy for fCAD.
  • Sex-specific cutoffs for troponin assays might enhance clinical utility.
  • The prognostic value of hs-cTnI and hs-cTnT in predicting MACE is similar.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
492
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
283
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
391
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
703
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
222